WO2021090214A2 - Berbérine bertrypanosomial®, ses compositions et leur utilisation - Google Patents

Berbérine bertrypanosomial®, ses compositions et leur utilisation Download PDF

Info

Publication number
WO2021090214A2
WO2021090214A2 PCT/IB2020/060383 IB2020060383W WO2021090214A2 WO 2021090214 A2 WO2021090214 A2 WO 2021090214A2 IB 2020060383 W IB2020060383 W IB 2020060383W WO 2021090214 A2 WO2021090214 A2 WO 2021090214A2
Authority
WO
WIPO (PCT)
Prior art keywords
berberine
formulation
alternatively
composition
starch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2020/060383
Other languages
English (en)
Other versions
WO2021090214A3 (fr
Inventor
Andrea Lacorte
Elisa BRILLI
Germano Tarantino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alesco SRL
Original Assignee
Alesco SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT102019000020300A external-priority patent/IT201900020300A1/it
Priority claimed from IT102019000020316A external-priority patent/IT201900020316A1/it
Priority claimed from IT102019000020290A external-priority patent/IT201900020290A1/it
Application filed by Alesco SRL filed Critical Alesco SRL
Publication of WO2021090214A2 publication Critical patent/WO2021090214A2/fr
Publication of WO2021090214A3 publication Critical patent/WO2021090214A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to a berberine formulation in solid form, called "sucrosomial ® berberine” (sucrosomial ® is a registered trademark on behalf of Pharmanutra S.p.A and Alesco S.r.l.) or "Ultraberb”, comprising or, alternatively, consisting of berberine, a lecithin and a first agent selected from a withster (alternatively called fatty acid carbohydrate ester), a cyclodextrin, a fatty acid, a chitosan derivative and a gum, preferably acutester or a gum.
  • the present invention relates to a composition, preferably in solid form, comprising said sucrosomial ® berberine and, optionally, red fermented rice, and the use thereof in the treatment of a disease, symptom and/or disorder related with a dyslipidaemia or an impairment of the lipid metabolism, in particular hypercholesterolemia, and/or an impairment of the glucose metabolism.
  • the present invention relates to a process for the preparation of said sucrosomial ® berberine.
  • the present invention also relates to a bergamot formulation in solid form, called “Ultraberg”, comprising or, alternatively, consisting of bergamot (or bergamot extract), a lecithin and a first agent selected from a withster (alternatively called fatty acid carbohydrate ester), a chitosan derivative and a gum, preferably acutester or a gum.
  • the present invention relates to a composition, preferably in solid form, comprising said sucrosomial ® bergamot and, optionally, red fermented rice, and the use thereof in the treatment of a disease, symptom and/or disorder related with a dyslipidaemia or an impairment of the lipid metabolism, in particular hypercholesterolemia, and/or an impairment of the glucose metabolism.
  • the present invention relates to a process for the preparation of said sucrosomial ® bergamot.
  • Dyslipidaemias consist of a plasma increase in cholesterol, triglycerides, or both, or a low level of HDL cholesterol contributing to the development of atherosclerosis.
  • the causes can be primitive (genetic) or secondary.
  • the diagnosis is made by measuring the plasma levels of total cholesterol, triglycerides and individual lipoproteins. Treatment entails dietary changes, physical exercise and lipid-lowering drugs.
  • Berberine is usually found in roots, rhizomes, stems or trunks and in the bark.
  • Berberine has been shown to be effective in controlling LDL cholesterol, plasma triglyceride and HDL cholesterol levels, as well as blood sugar level.
  • Berberine has many mechanisms of action which are still subject of study. It seems that berberine can reduce the mRNA levels of PCSK9 ( Proprotein Convertase Subtilisin / Kexin Type 9) and thus the plasma levels of this protein. On the other hand, berberine also exerts a direct effect on LDL receptors, stabilising the mRNA coding thereof. The combination of these two mechanisms (mRNA stabilisation and decrease in PCSK9 activity) leads to an increase in LDL receptors on the surface of hepatic cells and cellular LDL uptake, thus decreasing plasma LDL levels.
  • PCSK9 Proprotein Convertase Subtilisin / Kexin Type 9
  • Berberine also decreases plasma triglyceride levels through opposite effects on Map kinase (which is inhibited) and on AMP kinase (enhanced).
  • berberine has proven to be capable of increasing plasma HDL cholesterol levels by a few percentage points.
  • CN 106511260 describes a xerogel comprising berberine, a cyclodextrin, and lecithin. This xerogel can then be processed to obtain a solid pellet.
  • this document does not describe a solid formulation as claimed in the present context, it even less describes a similar formulation for use in the preventive and/or curative treatment of decrease or normalisation of the plasma levels of plasma levels of total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides.
  • sucrosomial ® berberine a novel berberine formulation, called sucrosomial ® berberine, and compositions comprising said sucrosomial ® berberine.
  • An object of the present invention is to provide a novel berberine formulation, called sucrosomial ® berberine, and compositions comprising said sucrosomial ® berberine capable of increasing the effectiveness in the treatment of disorders related with dyslipidaemias or impairments of the lipid metabolism and/or impairments of the glucose metabolism.
  • sucrosomial ® berberine and the compositions thereof, subject of the present invention are stable over time from the chemical-physical and organoleptic point of view.
  • sucrosomial ® berberine and the compositions thereof have no relevant side effects, they are well tolerated and, thus, they can be administered to all categories of subjects, including paediatric subjects, adolescents, pregnant women and the elderly.
  • sucrosomial ® berberine and the compositions thereof is easy to implement or prepare and cost-effective in proportion to the treatment potential.
  • the berberine formulation of the invention (sucrosomial ® berberine) is easily processable to provide the compositions of the present invention, preferably in solid form for oral use.
  • Figure 1 HPLC analysis on water-soluble extracts of berberine as such and sucrosomial ® berberine powders.
  • Figure 2 cytotoxic effect of berberine as such and sucrosomial ® berberine on the HepG2 cell line.
  • Figure 3 effect of berberine as such and sucrosomial ® berberine on LDL cholesterol uptake in the Huh7 cell line.
  • Figure 4A and Figure 4B effect of berberine as such and sucrosomial ® berberine on levels of mRNA and LDL receptor cell proteins (LDLR) in the Huh7 cell line.
  • LDLR LDL receptor cell proteins
  • Figure 5 effect of berberine as such and sucrosomial ® berberine on the expression of GK and AMPK in the Huh7 cell line.
  • Figure 6 effect of berberine as such and sucrosomial ® berberine on the intracellular glycogen content in the Huh7 cell line.
  • Figures 7A, 7B, 7C, 7D Cytotoxicity activity of Atomised berberine (BBR-A) and Ultra-berberine (U-BBR).
  • BBR-A Atomised berberine
  • U-BBR Ultra-berberine
  • Figure 8A, 8B, 8C Effect of atomised berberine and ultra-berberine on the expression of LDLR and PCSK9 in Huh7 cells.
  • Cells were cultured with MEM/0.4% FCS in the presence or absence of increasing concentrations of atomised berberine (BBR-A) and ultra-berberine (U BBR). After 24 hours, total protein extracts and protein expression evaluated by means of Western blot analysis were prepared. GAPDFI was used as a load control. Densitometric readings were evaluated using ImageLab software. Formulations vs control: * p ⁇ 0.05; ** p ⁇ 0.01; *** p ⁇ 0.001.
  • Figure 9 Effect of bergamot and ultra- bergamot on the expression of FIMG-CoA reductase in Huh7 cells.
  • Cells were cultured with MEM/0.4% FCS in the presence or absence of increasing concentrations of bergamot (BE) and ultra-bergamot (U-BE). After 24 hours, total protein extracts and protein expression evaluated by means of Western blot analysis were prepared.
  • GAPDFI was used as a load control. Densitometric readings were evaluated using ImageLab software. Formulations vs control: * p ⁇ 0.05; ** p ⁇ 0.01.
  • Figure 10 Effect of the U-BBR formulation on the LDL-DIO uptake by Huh7 cells.
  • Cells were cultured with MEM/0.4% FCS in the presence or absence of increasing concentrations of ultra-berberine (U-BBR).
  • U-BBR ultra-berberine
  • Forming an object of the present invention is a berberine formulation in solid form called sucrosomial ® berberine (in short, berberine formulation of the invention) comprising or, alternatively, consisting of: (a) berberine, (b) a lecithin (c) at least one first agent selected from the group comprising or, alternatively, consisting of: (c-i) a fatty acid carbohydrate ester (alternatively called145); (c-ii) at least one cyclodextrin, preferably an alpha-cyclodextrin; (c-iii) at least one fatty acid having a number of carbon atoms comprised in the range from C6 to C18, preferably from C12 to C18; (c-iv) at least one chitosan derivative, preferably carboxymethyl chitosan; (c-v) a gum selected from carrageenan, acacia gum and a mixture of carrageenan and acacia gum; and
  • sucrosomial ® berberine may be an atomised "sucrosomial ® berberine” or a non-atomised “sucrosomial ® berberine”.
  • atomised sucrosomial ® berberine is used to indicate a formulation comprising a berberine carried on a carrier and/or non-atomised), a lecithin and said first agent (such as (c-i)-(c-iv) or (c-v)).
  • said berberine (a) is an atomised berberine.
  • atomised berberine is used to indicate a berberine carried on a carrier and obtained by means of an atomisation process (as described hereinafter): berberine is added to a carrier (or carrier material, for example a starch) in the presence of a solvent (for example water) to form a mixture (or intermediate product) and said mixture is subjected to an atomisation (or nebulisation) step to obtain said "atomised berberine”. Subsequently, the atomised “berberine” is processed with lecithin and said first agent (such as (c-i)-(c-iv) or (c-v)) to obtain said atomised "sucrosomial ® berberine”.
  • a carrier or carrier material, for example a starch
  • a solvent for example water
  • non-atomised sucrosomial ® berberine is used to indicate a formulation comprising a berberine as such (i.e. not carried on a carrier or non-atomised), a lecithin and said first agent (such as (c-i)-(c-iv) or (c-v)) and, optionally, a starch.
  • berine indicates both berberine as such and “atomised berberine”.
  • sucrosomial ® berberine in solid form called sucrosomial ® berberine (in short, berberine formulation of the invention) comprising or, alternatively, consisting of: (a) berberine (berberine as such or atomised berberine), (b) a lecithin and (c) at least one first agent comprising or, alternatively, consisting of (c-i) a fatty acid carbohydrate ester (alternatively called145).
  • fatty acid carbohydrate ester “sucrester” and “sucrose fatty acid ester”, whether in singular or plural form, are synonyms and they identify the same compound.
  • berberine (a), comprised in the berberine formulation of the invention (sucrosomial ® berberine) together with (b), (c) such as (c-i) or (c-ii) or (c-iii) or (c-iv) or (c-v) and, optionally, (d), is obtained by extracting one or more parts (for example, roots, trunks, rhizomes, bark) of a plant of the genus fierbens, preferably of a plant of the species fierber/s aristata (DC.) or fierber/s vulgaris (L), according to conventional extraction methods, preferably aqueous extraction.
  • said berberine (a) is obtained by extracting the roots of the plant of the species Berberis aristata (DC.), preferably by means of aqueous extraction according to techniques known to the man skilled in the art.
  • said berberine (a) is a berberine HCI, preferably berberine HCI granular or powder, obtained by the extraction of the species Berberis aristata (DC.), preferably by means of aqueous extraction according to techniques known to the man skilled in the art; for example, granular HCI granular obtained by extraction from fierber/s Aristata DC. And identifiable withCAS No: 633-65-8 and having the following technical characteristics: excipients: pre-gelatinised starch and microcrystalline cellulose, formula: C20H18NO4CI, MW: 371.81, loss on drying ⁇ 13.0%, residue after ignition ⁇ 0.2%, particle size >90% from 30 mesh to 120 mesh.
  • the (b) lecithin comprised in the berberine formulation of the invention (sucrosomial ® berberine) together with (a), (c) such as (c-i) 0 (c-ii) 0 (c-iii) 0 (c-iv)o (c-v) and, optionally, (d), is a lecithin in solid form, such as for example in the form of powder or granules, preferably solid lecithin for example E322, more preferably a solid lecithin for example E322 selected from sunflower lecithin, corn lecithin and soya lecithin; even more preferably solid sunflower lecithin E322, for example allergen free solid sunflower lecithin E322 (e.g. in form of powder or granules).
  • a lecithin in solid form such as for example in the form of powder or granules, preferably solid lecithin for example E322, more preferably a solid lec
  • allergen free is used to indicate that it does not have any allergens as residues.
  • E322 only defines that lecithin is a food additive according to the Directive 95/2/EC of 20.2.95 published in the Official Journal (in short, O.J.) of the European Union No. L61 of 18.3.95.
  • the lecithin is a mixture of phosphoric acid, choline, fatty acids, glycerol, glycolipids, triglycerides and phospholipids.
  • Phospholipids represent the main components thereof; the latter derive from the structure of the triglycerides, where a fatty acid is replaced by a phosphate group which confers a negative charge and thus polarity to the molecule; this molecule is known by the generic name phosphatide.
  • a more complex organic molecule - generally serine, choline, ethanolamine, inositol or a single hydrogen atom - is bound to the phosphate group - through an ester bond - obtaining a phospholipid called, respectively, phosphatidylserine, phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol or phosphatidic acid.
  • lecithin is often represented by phosphatidylcholine.
  • Phospholipids are characterised by a water-soluble polar head, which dissolves well in water, while the two saturated fatty acids represent the two non-polar tails, that are not water-soluble but lipophilic.
  • lecithin is a natural emulsifier and it has a secondary antioxidant function being rich in natural antioxidant substances.
  • the lecithin may for example have a water content at a % by weight comprised in a range from 1.5% to 4.5% with respect to the lecithin, preferably from 2% to 4%, even more preferably from 2.5% to 3.5%.
  • lecithin be a sunflower lecithin E322, preferably in form of powder or granules, lecithin may for example have a glucose content at a % by weight comprised in the range from 20% to 60% with respect to the weight of lecithin, preferably from 30% to 50%, for example about 45%.
  • a (b) sunflower lecithin E322, preferably in form of powder or granules, that can be used % in the context of the present invention may have the following composition at a % by weight (chemical/physical analysis): sunflower lecithin from 40% to 50%, carbohydrates from 40% to 50% (for example about 42%), proteins from 6% to 10%, ashes from 3% to 8%, moisture from 2% to 5% and another flowing agent from 0.5% to 1.5%.
  • said (c-i)hester comprised in the berberine formulation of the invention (sucrosomial ® berberine) together with (a), (b) and, optionally, (d), is atrister E473, preferably asupplementaryster E473, more preferably atrister E473 comprising at least 70% by weight, with respect to the total weight of the interrupted acid, of monoesters obtained through the esterification of sucrose with one or more fatty acids of plant origin, preferably stearic acid and/or palmitic acid.
  • said (c-i)ester comprised in the berberine formulation of the invention (sucrosomial ® berberine) together with (a), (b) and, optionally, (d), does not comprise or, alternatively, does not consist of a diglycerol fatty acid ester.
  • “Sucresters” are generally obtained from the esterification of the fatty acids or from the trans-esterification of fatty acids methyl esters with carbohydrates (also called saccharides). Sucrose (monosaccharide) and polysaccharides are generally the carbohydrates used. This is why atsters are also referred to as “sucrose fatty acid esters”. The chemical-physical properties of these compounds depend on the number and the type of esterified fatty acids.
  • compositions are essentially emulsifiers and they are added to the compositions so as to determine a greater stabilisation of an aqueous phase with a fatty phase.
  • said Atster E473 can be aester having a HLB (hydrophilic-lipophilic balance) value comprised in the range from 14 to 18, preferably a HLB value of about 15 or 16.
  • HLB hydrophilic-lipophilic balance
  • a (c-i)utester (E473) that can be used in the context of the present invention may have the following composition by weight: total ester content of at least 90%, of which at least 70% by weight, with respect to the total weight of the interruptedster, of monoesters obtained through the esterification of sucrose with one or more fatty acids of plant origin, preferably stearic acid and/or palmitic acid; free fatty acid content (such as oleic acid) not exceeding 3 %; free sucrose content not exceeding 2 %; moisture not exceeding 4 %; acid value not exceeding 5.
  • An example of (c-i) commercialiser that can be used in the context of the present invention is: sucrose esters SP70 produced by Chimab S.p.A -Italia.
  • the berberine formulation of the invention further comprises, together with (a), (b) and (c) such as (c-i) or (c-ii) or (c-iii) or (c-iv) or (c-v), a (d) starch of plant origin, preferably gelatinised or pre-gelatinised; preferably, said (d) starch of plant origin is selected from rice starch and/or corn starch; preferably, said (d) starch of plant origin is rice starch (Oryza sativa) or native rice starch; more preferably, said (d) starch of plant origin is pre-gelatinised rice starch.
  • a pre-gelatinised rice starch that can be used in the context of the present invention may for example have the following chemical/physical characteristics: moisture not exceeding 7%; protein content not exceeding 1%; ash content not exceeding 1%; pH (solution 10%) comprised from 5.5 to 7.5, density 0.40- 0.48 g / cm3; minimum starch content at 97% and fats not exceeding 0.1%.
  • An example of commercial pre- gelatinised rice starch is AX-FG-P produced by Reire Sri -Italia.
  • the berberine formulation of the invention in solid form comprises or, alternatively, consists of: (a) berberine (berberine as such or atomised berberine), (b) a lecithin, (c-i) atriol and (d) a starch of plant origin.
  • the berberine formulation of the invention in solid form comprises or, alternatively, consists of: (a) berberine (berberine as such or atomised berberine), preferably berberine HCI granular or powder (b) a solid lecithin (E322), preferably solid sunflower lecithin (E322), more preferably allergen free solid sunflower lecithin (E322); (c- i) ahester (E473), preferablyentrester (E473) comprising at least 70% by weight, with respect to the total weight of the interruptedster, of monoesters obtained through the esterification of sucrose with one or more fatty acids of plant origin, preferably stearic acid and/or palmitic acid; and (d) pre-gelatinised starch of plant origin, preferably pre-gelatinised rice starch.
  • berberine as such or atomised berberine
  • E322 solid sunflower lecithin
  • E473 preferably allergen free solid sunflower lecithin
  • the berberine formulation of the invention in solid form comprises or, alternatively, consists of: (a) berberine (berberine as such or atomised berberine) or berberine HCI granular or powder; (b) an allergen free solid sunflower lecithin (E322); (c-i) ahester (E473) comprising at least 70% by weight, with respect to the total weight of the interrupted acid of sucrose with one or more fatty acids of plant origin, preferably stearic acid and/or palmitic acid; and (d) a pre-gelatinised rice starch.
  • the berberine formulation of the invention comprises, together with (a), (b) and, optionally, (d) according to any one of the described embodiments, said at least one first agent (c) comprising or, alternatively, consisting of (c-ii) at least one cyclodextrin, preferably an alpha-cyclodextrin.
  • the berberine formulation of the invention comprises, together with (a), (b) and, optionally, (d) according to any one of the described embodiments, said at least one first agent (c) comprising or, alternatively, consisting of (c-iii) at least one fatty acid having a number of carbon atoms comprised in the range from C6 to C18, preferably from C12 to C18.
  • the berberine formulation of the invention comprises, together with (a), (b) and, optionally, (d) according to any one of the described embodiments, said at least one first agent (c) comprising or, alternatively, consisting of (c-iv) at least one chitosan derivative, preferably carboxymethyl chitosan.
  • said (c-iv) replaces (c-i).
  • the berberine formulation of the invention further comprises, together with (a), (b), (c-i) and, optionally, (d), at least one or two or three of said first agents selected from the group comprising or, alternatively, consisting of: (c-ii) a cyclodextrin, (c-iii) a C6-C18 fatty acid isomer, (c-iv) a chitosan derivative, and mixtures thereof.
  • said (c-ii), (c-iii) and/or (c-iv) are additional to (c-i)
  • the cyclodextrins are natural cyclic oligosaccharides consisting of 6, 7 or 8 monomers of D- (+)glucopyranose joined together by an a, 1-4 glycosidic and closed-loop bond.
  • Alpha-cyclodextrin is an oligosaccharide with 6 monomers of D-(+)glucopyranose.
  • An example of a (c-ii) commercial cyclodextrin that can be used in the context of the present invention is the cyclodextrin Cavamax® W6 Food (CAS 10016-20-3) sold by Wecker Chemie AG.
  • Said first agent (c-iii) can be any isomer of a medium chain fatty acid C6-C18, for example any cis isomer or trans isomer of any fatty acid having from 6 to 18 carbon atoms.
  • Chitosan is a linear polysaccharide consisting of D-glucosamine and N-acetyl-D-glucosamine, linked by b(1- 4) bonds.
  • the expression chitosan derivative is used to indicate, by way of non-limiting example in the context of the present invention, any compound that can be obtained using chitosan or a derivative thereof or a precursor thereof as the starting material and subjecting said starting material to chemical transformations known to the man skilled in the art, so that said chitosan derivative has characteristics such to confer to said (a) mineral (cation of the mineral) comprised in the preparation (or sucrosomial ® mineral) an increased bioavailability and absorption capacity in the organism.
  • FR berberine formulation of the invention (sucrosomial ® berberine), in solid form, are comprised in the present invention:
  • - FRp comprising or, alternatively, consisting of (a), (b), (c-ii), (c-iii) and (c-iv) and, optionally, (d); wherein in all said embodiments comprised from FRa to FRp the components called (a), (b), (c-i), (c-ii), (c- iii) and (c-iv) are as defined in the present invention; and wherein it is not present in embodiments FRh to FRp (c-i).
  • said (a) berberine such as berberine as such or atomised berberine, is comprised in a range from 10% to 90%, preferably from 30% to 80%, more preferably from 40% to 70%, for example about 51+1%;
  • said (b) lecithin preferably solid lecithin (E322), is comprised in a range from 0.05% to 20%, preferably from 0.1% to 10%, more preferably from 0.5% to 2%, for example about 1+0,5%;
  • said (c) first agent such as (c-i) or (c-ii) or (c-iii) or (c-iv), preferably (c-i)utester (E473), is comprised in a range from 1% to 75% with respect to the weight of the preparation, preferably from 1% a 60%, more preferably from 5% to 40%, for example about 22+1 %;
  • said (d) starch preferably pre-gelatinised rice starch, is comprised in a range from 5% to 88%, preferably from 10% to 60%, more preferably from 15% to 40%, for example about 17+1% or 10+1%.
  • Forming an object of the present invention is a composition (in short, composition of the invention), preferably in solid form, comprising or, alternatively, consisting of: the berberine formulation of the invention (sucrosomial ® berberine) comprising or, alternatively, consisting of (a), (b), (c) such as (c-i) or (c- ii) or (c-iii) or (c-iv) or (c-v) and, optionally, (d) according to any one of the embodiments described in the present invention and, optionally, at least one acceptable pharmaceutical or food grade additive and/or excipient.
  • the berberine formulation of the invention aerocrosomial ® berberine
  • Said at least one acceptable pharmaceutical or food grade additive and/or excipient can be selected from all substances known to the man skilled in the pharmaceutical art or skilled in preparing food products, such as preservatives, emulsifiers and/or thickeners such as for example hydroxymethyl cellulose, sweeteners, dyes such as for example E171 dye, natural and artificial flavours, antioxidants, stabilisers, fillers, anticaking agents such as for example vegetable magnesium stearate, fatty acid magnesium salts and silicon dioxide, bulking agents such as for example microcrystalline cellulose and mixtures thereof.
  • preservatives such as for example hydroxymethyl cellulose
  • sweeteners dyes such as for example E171 dye, natural and artificial flavours, antioxidants, stabilisers
  • anticaking agents such as for example vegetable magnesium stearate, fatty acid magnesium salts and silicon dioxide
  • bulking agents such as for example microcrystalline cellulose and mixtures thereof.
  • the composition of the invention comprises a berberine formulation of the invention (sucrosomial ® berberine) comprising or, alternatively, consisting of (a), (b), (c-i) and, optionally, (d) according to any one of the described embodiments.
  • composition of the invention comprising a berberine formulation of the invention (sucrosomial ® berberine) comprising or, alternatively, consisting of (a), (b), (c) such as (c-i) or (c-ii) or (c-iii) or (c-iv) or (c-v) and, optionally, (d) according to any one of the described embodiments, further comprises at least one or more further active components selected from the group comprising or, alternatively, consisting of:
  • (f) at least one organic salt or inorganic salt preferably selected from the group comprising or, alternatively, consisting of: (f-i) magnesium glycinate, (f-ii) selenium methionine, (f-iii) zinc gluconate and mixtures thereof;
  • At least one antioxidant preferably selected from the group comprising or, alternatively, consisting of: (g-i) N-acetylcysteine (NAC), (g-ii) Coenzyme Q10 (CoQ10), (g-iii) Acetyl-L-carnitine (ALC) and mixtures thereof;
  • At least one bacterial strain belonging to the genus Lactobacillus or Bifidobatterium preferably of the species selected from the group comprising or, alternatively, consists of: Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus reuteri, Lactobacillus rhamnosus, Bifidobacterium lungum, Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium bifidum and mixtures thereof; and
  • red fermented rice ( Monascus purpureus ), preferably red fermented rice titrated in monacolin to a % by weight comprised in a range from 2% to 10%, preferably from 3% to 7%, more preferably to about 5%, with respect to the weight of red rice (in short, % w/w), wherein said monacolin is preferably monacolin K.
  • Red fermented rice is the product of the fermentation of the common rice (Oryza sativa) by the yeast Monascus purpureus (red yeast), according to the techniques known to the man skilled in the art.
  • the production process of red fermented rice in Japan is known as Koji and is a very ancient technique.
  • the common rice takes the red colouring typical of yeast and it is enriched with many active substances, including monacolin, including monacolin K.
  • the composition of the invention comprises a berberine formulation of the invention (sucrosomial ® berberine) comprising or, alternatively, consisting of (a), (b), (c) such as (c-i) or (c- ii) or (c-iii) or (c-iv), or (c-v) and, optionally, (d) according to any one of the described embodiments and it further comprises (I) red fermented rice ( Monascus purpureus ), preferably red fermented rice titrated in monacolin to a % by weight comprised in a range from 2% to 10%, preferably from 3% to 7%, more preferably to about 5%, with respect to the weight of red rice, wherein said monacolin is preferably monacolin K.
  • the composition of the invention comprises a berberine formulation of the invention (sucrosomial ® berberine) comprising or, alternatively, consisting of (a), (b), (c-i) and, optionally, (d) according to any one of the described embodiments, and said composition further comprises (I) red fermented rice ( Monascus Purpureus ), preferably red fermented rice titrated in monacolin to a % by weight comprised in a range from 2% to 10%, preferably from 3% to 7%, more preferably to about 5% with respect to the weight of red rice, wherein said monacolin is preferably monacolin K.
  • red fermented rice Monascus Purpureus
  • said (I) red fermented rice ( Monascus purpureus) titrated in monacolin or monacolin K to 2%- 10% or 3%-7% or about 5% w/w, is present in the composition of the invention at a % by weight so that said monacolin or monacolin K is comprised in the composition in a range from 0.05% to 1.00% with respect to the total weight of the composition, preferably from 0.10% to 0.50%.
  • composition of the invention preferably in solid form, are comprised in the present invention:
  • - FRd1 comprising or, alternatively, consisting of (I), (a), (b), (c-i), (c-ii) and (c-iii) and, optionally, (d);
  • FRp1 comprising or, alternatively, consisting of (I), (a), (b), (c-ii), (c-iii) and (c-iv) and, optionally, (d); wherein in all said embodiments comprised from FRa1 to FRp1, the components called (a), (b), (c-i), (c-ii), (c-iii) and (c-iv) are as defined in the present invention; and wherein it is not present in embodiments FRh1 to FRp1 (c-i).
  • each single vitamin (e) and/or salt (f) is present in the composition of the invention at an amount equal to 100% RDA (recommended dietary allowance).
  • each single antioxidant substance (g) is present in the composition of the invention in an amount equal to 100 mg/day.
  • compositions of the invention are in solid form, for example in solid form as such or in mouth-soluble solid form (or mouth-dispersible form, or that dissolve in the oral cavity), preferably in solid form as such.
  • compositions of the invention can be in liquid form, for example in the form of solution, dispersion or suspension of a solid in a liquid, or in semi-solid form, for example in form of creams or gels or soft-gels.
  • compositions of the invention are formulated for oral administration (in short, per os).
  • compositions of the invention are in solid form for oral administration, such as for example powder, granules, flakes, tablets or capsules.
  • compositions of the invention are in tablet form, said tablet may have a weight comprised in the range from 200 mg to 2000 mg, for example a hard tablet from 800 mg to 1000 mg.
  • Said tablets may be coated or filmed with one or more coating layers or films capable of going past the gastric barrier.
  • Said coating may comprise bee wax or a sugar-based solution.
  • compositions of the invention are in the form of a capsule
  • said capsule may be of hard gelatine or soft gelatine or soft-gel; preferably a gelatine capsule may have a weight comprised in the range of from 100 mg to 1500 mg, more preferably about 800 mg.
  • composition of the invention comprising said berberine formulation of the invention (sucrosomial ® berberine) according to any one of the embodiments described in the present invention, may be a pharmaceutical composition, a medical device composition, a dietary supplement, a food or novel food or nutraceutical composition.
  • the expression "medical device” is used in the meaning according to the Italian Legislative Decree n° 46 dated 24 February 1997 or according to the new Medical Device Regulation (EU) 2017/745 (MDR).
  • Forming an object of the present invention is the composition of the invention and the berberine formulation of the invention (sucrosomial ® berberine), according to any one of the described embodiments, for use as medicament.
  • composition of the invention and the berberine formulation of the invention is the composition of the invention and the berberine formulation of the invention (sucrosomial ® berberine), according to any one of the described embodiments, for use in a method for preventive and/or curative treatment of a disease, symptom and/or disorder related with a dyslipidaemia or an impairment of the lipid metabolism, in subjects in need.
  • said diseases, symptoms and/or disorders related with a dyslipidaemia or impairment of the lipid metabolism are selected from:
  • LDL or LDL cholesterol low-density lipoprotein
  • HDL or HDL cholesterol high-density lipoprotein
  • abnormal levels is used to indicate higher or lower levels with respect to the ranges within which triglyceride or LDL or HDL levels fall in the blood or plasma of healthy subjects as determined by health care organisations (in short, normal or near optimal ranges). Said standard ranges may vary over time and from population to population.
  • LDL cholesterol should ideally not exceed 100 mg/dl, although levels below 160 mg/dl are considered normal.
  • HDL cholesterol should be equal to or above 50 mg/dl.
  • Total cholesterol is considered “moderately high” when the blood concentrations thereof are between 200 and 239 mg/dl and "high” when equal to or above 240 mg/dl.
  • LDL-cholesterol concentration is instead considered “almost optimal” for values between 100 and 129 mg/dl, “moderately high” for values between 130 and 159 mg/dl, “high” for values between 160 and 189 mg/dl, and "very high” for values exceeding 190 mg/dl.
  • the composition of the invention and the berberine formulation of the invention are for use in a method for the preventive and/or curative treatment of (i) hypercholesterolemia, more preferably the composition of the invention is for use in a method for preventive and/or curative treatment of (ii) modulation or decrease in plasma LDL cholesterol levels and/or of (iii) modulation or increase in plasma HDL cholesterol levels and/or (iv) modulation or decrease in plasma triglyceride levels.
  • Atherosclerosis is characterised by the presence of inhomogeneous intima plaques (atheromas) which invade the lumen of medium and large arteries; the plaques contain lipids, inflammatory cells, smooth muscle cells and connective tissue. Risk factors comprise dyslipidaemia, diabetes, cigarette smoking, family medical history, sedentary life, obesity and hypertension. Symptoms appear when plaque growth or rupture obstructs or decreases blood flow; symptoms vary depending on the artery involved. Atherosclerosis is responsible for coronary and cerebrovascular diseases (for example, stroke).
  • Metabolic syndrome is characterised by a large waist circumference (due to excess abdominal fat), arterial hypertension, impaired fasting plasma glucose or insulin resistance and dyslipidaemia. The causes, complications, diagnosis and treatment are similar to those of obesity.
  • the term "subject/s” is used to indicate human or animal subjects, preferably mammals (e.g. pets such as dogs, cats, horses, sheep or cattle).
  • mammals e.g. pets such as dogs, cats, horses, sheep or cattle.
  • the compositions of the invention are for use in treatment methods for human subjects.
  • composition of the invention and the berberine formulation of the invention is the composition of the invention and the berberine formulation of the invention (sucrosomial ® berberine), according to any one of the described embodiments, for use in a method for preventive and/or curative treatment of a disease, symptom and/or disorder related with an impairment of the glucose metabolism, in subjects in need.
  • said disease, symptom and/or disorder related with an impairment of the glucose metabolism is selected from:
  • diabetes preferably type 2 diabetes mellitus
  • the term “deregulation of blood glucose level” is used to indicate that the glucose level is lower or higher with respect to the range within which the glucose levels of healthy subjects fall as determined by health care organisations (in short, ranges or normal values).
  • normal “blood glucose values are considered to be those comprised in the range from 60 to 110 mg/dL.
  • an amount of the composition of the invention comprising or, alternatively, consisting of sucrosomial ® berberine so as to provide the administration of an amount of berberine as such comprised in the range from 100 mg to 1,500 mg, preferably from 300 mg to 800 mg, more preferably from 400 mg to 600 mg, for example about 500 mg.
  • composition of the invention comprises the sucrosomial ® berberine formulation and red fermented rice ( Monascus purpureus), preferably red fermented rice titrated in monacolin or monacolin K to 2%-10% or 3%-6% or about 5% w/w
  • red fermented rice preferably red fermented rice titrated in monacolin or monacolin K to 2%-10% or 3%-6% or about 5% w/w
  • red fermented rice preferably red fermented rice titrated in monacolin or monacolin K to 2%-10% or 3%-6% or about 5% w/w, comprised in the range from 10 mg to 100 mg, preferably from 40 mg to 80 mg, more preferably from 50 mg to 70 mg, for example about 60 mg.
  • the composition of the invention comprises the sucrosomial ® berberine formulation and red fermented rice titrated in monacolin or monacolin K to about 5% w/w
  • the daily oral administration of an amount of the composition of the invention so as to provide the administration of an amount of berberine as such of about 500 mg and an amount of red fermented rice ( Monascus purpureus) titrated in monacolin or monacolin K to about 5% w/w, of about 60 mg.
  • the composition of the invention is about 1000 mg and it comprises about 500 mg of berberine as such and about 60 mg of red fermented rice titrated in monacolin or monacolin K to about 5% w/w (equivalent to about 3 mg of monacolin or monacolin K).
  • the compositions of the invention or the berberine formulation of the invention can be administered for a period of time comprised in the range from 7 days to 120 days.
  • Forming an object of the present invention is to the use of the composition of the invention or of the berberine formulation of the invention (sucrosomial ® berberine) in the therapeutic or non-therapeutic treatment of a disease, symptom and/or disorder related with a dyslipidaemia or impairment of the lipid metabolism, such as, for example, hypercholesterolemia, abnormal levels of blood triglycerides, abnormal levels of blood lipoproteins, atherosclerosis and related coronary and cerebrovascular diseases, preferably stroke and metabolic syndrome.
  • a disease, symptom and/or disorder related with a dyslipidaemia or impairment of the lipid metabolism such as, for example, hypercholesterolemia, abnormal levels of blood triglycerides, abnormal levels of blood lipoproteins, atherosclerosis and related coronary and cerebrovascular diseases, preferably stroke and metabolic syndrome.
  • composition of the invention or the berberine formulation of the invention in the therapeutic or non-therapeutic treatment of a disease, symptom and/or disorder related with an impairment of the glucose metabolism, such as, for example, diabetes, preferably type 2 diabetes mellitus, hyperglycaemia, insulin resistance, high glucose uptake level, deregulation of the blood glucose level and metabolic syndrome conditions.
  • Forming an object of the present invention is a method for the preventive and/or curative treatment of a disease, symptom and/or disorder related with a dyslipidaemia or impairment of the lipid metabolism, such as, for example, hypercholesterolemia, abnormal levels of blood triglycerides, abnormal levels of blood lipoproteins, atherosclerosis and related coronary and cerebrovascular diseases, preferably stroke, and metabolic syndrome, wherein said method provides for the administration of the composition of the invention or of the berberine formulation of the invention (sucrosomial ® berberine) to a subject in need.
  • a disease, symptom and/or disorder related with a dyslipidaemia or impairment of the lipid metabolism such as, for example, hypercholesterolemia, abnormal levels of blood triglycerides, abnormal levels of blood lipoproteins, atherosclerosis and related coronary and cerebrovascular diseases, preferably stroke, and metabolic syndrome
  • said method provides for the administration of the composition of the invention or of the berberine formulation of the invention
  • an object of the present invention is a method for the preventive and/or curative treatment of a disorder related with an impairment of the glucose metabolism, such as, for example, diabetes, preferably type 2 diabetes mellitus, hyperglycaemia condition, insulin resistance conditions, high glucose uptake condition, deregulation of blood glucose level and metabolic syndrome conditions, and of symptoms and/or disorders related with said conditions, wherein said method provides for the administration of the composition of the invention or the berberine formulation of the invention (sucrosomial ® berberine) to a subject in need.
  • a disorder related with an impairment of the glucose metabolism such as, for example, diabetes, preferably type 2 diabetes mellitus, hyperglycaemia condition, insulin resistance conditions, high glucose uptake condition, deregulation of blood glucose level and metabolic syndrome conditions, and of symptoms and/or disorders related with said conditions
  • said method provides for the administration of the composition of the invention or the berberine formulation of the invention (sucrosomial ® berberine) to a subject in need.
  • Forming an object of the present invention is a process for the preparation of the berberine formulation of the invention (sucrosomial ® berberine).
  • the term "sucrosomial ® berberine” indicates a berberine formulation that can be obtained by processing berberine (a) together with a lecithin (b), a first agent (c) such as a withster (c-i) or a cyclodextrin (c-ii) or a fatty acid (c-iii) or a chitosan derivative (c-iv) and, optionally, a starch (d), according to said first process or said second process, described above.
  • the "atomised berberine” comprised in the formulation of the present invention can be obtained by means of the following process (berberine atomisation process), which forms an object of the present invention.
  • Said berberine atomisation process comprises the following steps:
  • step (I) providing a first aqueous-based solvent, preferably water, in a container under stirring and heating and adding to said container a berberine, preferably a granular berberine, and plant starch, preferably rice starch, preferably at a by weight ratio comprised from 9:1 to 1:1, more preferably comprised from 4:1 to 2:1, understood as berberine/starch, to obtain an aqueous-based mixture of step (I);
  • a berberine preferably a granular berberine, and plant starch, preferably rice starch
  • step (II) subjecting said mixture of step (I) to a nebulisation/atomisation step to obtain an atomised (or nebulised) berberine, and, optionally,
  • the amount by weight of berberine (for example granular berberine) and starch, understood as the total solid fraction added to said aqueous-based solvent, preferably water, may be comprised from 20% to 60% by weight with respect to the total weight of said aqueous-based mixture of step (I), preferably comprised from 25% to 50%, even more preferably comprised from 20% to 45%.
  • the berberine used in the berberine atomisation process is in granular form.
  • the berberine in granular form has the advantage of being easy to handle and process.
  • the berberine used in the first step may be a commercially available food grade or pharmaceutically acceptable berberine as such, preferably granular berberine hydrochloride.
  • berberine Chloride Granular produced and distributed by Shanghai Freemen LifeScience Co. Ltd. 2500 Xiupu Road, Building 19, Kangqiao, Pudong, Shanghai 201315, China, may be used.
  • Berberine used as starting product may also contain food or pharmaceutical grade excipients.
  • the berberine that can be used in the first step of the process may have the following composition:
  • the berberine that can be used is free from allergens and harmful substances, such as heavy metals, pesticides or organic solvents.
  • the berberine that can be used in the present context may be derived from the "Berberis Aristata”.
  • Atomised/nebulised berberine that can be obtained from the atomisation/nebulisation step, for example atomising for example by means of electrostatic and ultrasonic atomisers, is a berberine devoid of allergens and harmful substances, such as heavy metals, pesticides or organic solvents. It is also a pharmaceutical or food grade berberine.
  • atomised/nebulised berberine obtained from the atomisation/nebulisation step
  • atomised berberine the atomised/nebulised berberine, obtained from the atomisation/nebulisation step
  • Nebulisation also called atomisation
  • atomisation is the separation of a liquid into very fine parts (drops), which is obtained, for example, by striking the liquid with a jet of air at high speed or by forcing the liquid to pass through an orifice having a very narrow through-flow section.
  • the narrower the through-flow section of the orifice the greater the pressure the fluid is subjected to.
  • electrostatic and ultrasonic atomisers which can be used in this context.
  • the atomized berberine that can be obtained from the atomisation step of the process may have the following composition:
  • atomised berberine may have a titre comprised from 70% to 90%, preferably comprised from 75% to 85%.
  • plant starch that can be used in the process reported herein is as described in the present context, i.e. plant starch, preferably gelatinised or pre-gelatinised starch of plant origin.
  • said starch of plant origin may be selected from the group comprising or, alternatively, consisting of rice starch and/or corn starch; preferably, it may be pre-gelatinised rice starch.
  • step (II) atomising said mixture obtained in step (I) obtaining an atomised berberine of step (II) (in powder form);
  • step (III) Sieving said atomised berberine obtained in step (II) with a screen having a nominal sieve opening comprised from 20 m to 500 pm, preferably comprised from 100 pm to 300 pm, for example an opening measuring 250 pm, to obtain said atomised berberine or sieved atomised berberine.
  • step (II) of atomising said mixture obtained in step (I) is carried out at a temperature comprised from 50°C to 250°C, preferably comprised from 150°C to 200°C, for a period of time comprised from 1 hour to 10 hours, preferably from 3 hours to 7 hours.
  • Temperatures are control parameters in the process; according to a preferred example:
  • the input temperature is around 185°C and it is managed by the modulation of the burner flame
  • the output temperature is around 80°C and it is managed by sending more or less liquid into the drying chamber, trying to reach the required temperature. The more liquid flows into the chamber, the more the temperature tends to drop while the less liquid flows into the chamber the more the temperature tends to rise.
  • said atomised berberine that can be obtained from the berberine atomisation process reported above.
  • said atomised berberine is extremely easy to handle and formulate.
  • Said atomised berberine may then be formulated by processing said berberine together with a lecithin (b), with a first agent (c) such as a withster (c-i) or a chitosan derivative (c-iv) or a gum (c-v) and, optionally, a starch (d), according to said first process or said second process, respectively described in WO 2014/009806 A1 from page 7 line 1 to page 8 line 20, and in WO 2014/009806 A1 from page 8 line 22 to page 10 line 21.
  • a lecithin b
  • a first agent such as acutester (c-i) or a chitosan derivative (c-iv) or a gum (c-v)
  • a starch d
  • said atomised berberine may be formulated by processing such berberine together with a lecithin (b), acutester (c-i) and/or a gum (c-v), or mixtures thereof, according to said first process or said second process, respectively described in WO 2014/009806 A1 from page 7 line 1 to page 8 line 20, and in WO 2014/009806 A1 from page 8 line 22 to page 10 line 21.
  • composition or other comprising a component at an amount "comprised in a range from x to y” is used to indicate that said component may be present in the composition or other at all the amounts present in said range, even though not specified, extremes of the range comprised.
  • the content of a component in a composition refers to the percentage by weight of that component with respect to the total weight of the composition.
  • compositions consisting of one or more components means that other components - besides the one, or the ones, indicated specifically - can be present and the indication that a composition "consists” of determined components means that the presence of other components is excluded.
  • the present invention also relates to a formulation in solid form, comprising or, alternatively, consisting of berberine (berberine as such or atomised berberine), and/or bergamot (or bergamot extract), a lecithin and a first agent selected from autester (alternatively called fatty acid carbohydrate ester), and a gum selected from the group comprising or, alternatively, consisting of: carrageenan, acacia gum and mixtures thereof.
  • the present invention relates to a composition, preferably in solid form, comprising the solid formulation reported above and, optionally, red fermented rice, and the use thereof in the treatment of a disease, symptom and/or disorder related with a dyslipidaemia or an impairment of the lipid metabolism, in particular hypercholesterolemia.
  • An object of the present invention is to provide a novel berberine and/or bergamot formulation and compositions comprising said berberine and/or bergamot formulation capable of increasing the effectiveness in the treatment of disorders related with dyslipidaemias or impairments of the lipid metabolism.
  • Said increase in effectiveness in the aforementioned treatment with the formulation according to the present invention or the compositions thereof with respect to treatment with berberine or bergamot as such could be due to an increase in blood bioavailability of berberine or bergamot, in turn due to an increase in intestinal or gastrointestinal absorption of berberine or bergamot thus formulated with respect to berberine or bergamot as such, when administered orally.
  • said increase in effectiveness could be due to other mechanisms and reasons.
  • berberine and/or bergamot and the compositions, subject of the present invention are stable over time from the chemical-physical and organoleptic point of view.
  • the berberine and/or the bergamot formulated according to the present invention and the compositions thereof have no relevant side effects, they are well tolerated and, thus, they can be administered to all categories of subjects, including paediatric subjects, adolescents, pregnant women and the elderly.
  • the berberine and/or bergamot formulation of the invention is easily processable to provide the compositions of the present invention, preferably in solid form for oral use.
  • said at least one agent (c-v) is a gum selected from the group comprising or, alternatively, consisting of carrageenan, acacia gum, and mixtures thereof.
  • the Carrageenan used in the present context is a food additive (thickener, stabiliser, gelling agent, emulsifier) allowed by European Union and Italian legislation and classified according to European Union legislation as a food additive "E407”.
  • Carrageenan (INCI Name: Carrageenan EU INCI Name: Chrondrus Chrispus Powder) is a product derived from carragheen, whose name derives from Carrageenan in Ireland.
  • Carrageenans are a complex group of linear polysaccharides, often sulphates, extracted from red algae. They are compounds with high molecular weight, i.e. very large molecules, characterised by repeating units of galactose and 3,6- anhydrogalactose (3,6-AG), both sulphates and non-sulphates. The units alternate with alpha 1-3 and beta 1-4 glycosidic bonds. Due to their structure, carrageenans behave like highly flexible molecules which curl to form helical structures. The spatial arrangement of the molecule generally confers them the ability to form a wide variety of different gels at room temperature. There are mainly three commercial classes of carrageenan: lambda, kappa and iota.
  • Carrageenan essentially consists of calcium, potassium, sodium and magnesium salts, sulfuric esters of polysaccharides which, by hydrolysis, give galactose and 3,6-anhydrogalactose. Carrageenan must not be hydrolysed or otherwise degraded chemically. It is in the form of a powder of coarse to fine consistency, yellowish to colourless in colour and basically odourless.
  • Carrageenan is a gelatine widely used for food, medicine and industrial purposes (used to clarify honey, beer, for the manufacture of paper, starch and more), especially in Ireland and in Great Britain; it is obtained by boiling two red algae on the rocky coast of the North Atlantic (Chondrus crispus and Gigartina mamitiosa) known by the names Irish moss or carragheen.
  • CSW-2 Genuvisco®, registered trademark, CP Kelco
  • Said carrageenan may be obtained according to processes known to those skilled in the art, for example by means of extraction from seaweed with water and Ca(OH)2 at high temperatures (e.g. slightly >1000C), neutralisation and precipitation with ethanol or isopropanol.
  • the acacia gum or gum arabic used in the present context is a food additive (thickener, stabiliser, emulsifier) allowed by European Union and Italian legislation and classified according to European Union legislation as a food additive ⁇ 414”.
  • Acacia gum is a natural gum of plant origin called acacia gum, since it is extracted from two species of sub-Saharan acacia: Acacia Senegal (L) and Acacia seyal.
  • acacia gum is a dry exudate obtained from trunks and branches of natural strains of acacias and the like.
  • Gum arabic is a complex mixture of high molecular weight polysaccharides (Mw 250,000-400,000), the calcium, magnesium and potassium salts thereof and glycoproteins which confer them one of its most important properties: the fact that it is fully edible (edibility). It consists of various components: arabinose, D-galactopyranose, rhamnopyranose, D-glucuronic acid, calcium, magnesium, potassium, sodium, mucilage.
  • gums and resins of plant origin Like almost all gums and resins of plant origin, it is produced by the plant following a natural process of "gummosis” that spontaneously activates to heal an insult (wound) to its surface integrity.
  • acacia gum that can be used in the present invention is an acacia gum having CAS-No 232-519-5, EINECS 232-519-5, compliant with E414, min. purity 99.9%, max. loss on drying 10%, max. total ash 4%, viscosity (20.0C) min 60 cps., specific optical rotation 30-600 (commercial example 386° gum arabic produced by Chimab, code 306045).
  • Acacia gums are obtained according to methods known to the man skilled in the art comprising the centrifugation, filtering, heating, drying steps.
  • the bergamot that can be used in the present invention is a pharmaceutical or food grade bergamot extract.
  • the terms “bergamot” and “bergamot extract” are used interchangeably.
  • the Bergamot is a plant similar to the orange of the family Rutacee ( Citrus bergamia), with fragrant white flowers and fruits from whose skin an essential oil widely used in perfumery and liqueur industries is extracted.
  • the extract can be obtained from fruits by grating, through a system of peeling machines that «scratch» the external of the fruit (bark) in a stream of water obtaining an emulsion conveyed in centrifuges that separate the essence from the water for the specific weight.
  • the bergamot extract according to the present invention is commercially available and is approved for pharmaceutical or food use.
  • said bergamot extract derives from the plant Citrus Bergamia Risso et. poit of the family of Rutacee.
  • the juice deriving from the fruit is normally used in this plant.
  • the bergamot that can be used in the present context has an aromatic odour, a yellow colour and can be in powder form.
  • bergamot extract produced and sold by Herbal&antioxidant derivatives (H&AD), with the identification code D: BRGESTPG can be used.
  • the bergamot that can be used in the present context is devoid of allergens and other harmful substances.
  • bergamot that can be used in the context of the present invention is the phytocompound described in patent document EP2364158 B1 from paragraph [0030] to [0033], incorporated in the present description for reference.
  • an object of the present invention is a solid formulation, comprising or, alternatively, consisting of:
  • (c-v) at least one gum selected from the group comprising or, alternatively, consisting of: carrageenan, acacia gum and mixtures thereof; and a mixture of (c-i) and (c-v).
  • a preferred embodiment of the present invention relates to a berberine formulation in solid form comprising or, alternatively, consisting of: (a) berberine (as such or atomised), (b) a lecithin (c) at least one first agent comprising or, alternatively, consisting of (c-i) atimester or a fatty acid carbohydrate ester.
  • a preferred embodiment of the present invention relates to a bergamot formulation in solid form comprising or, alternatively, consisting of: (a) bergamot, (b) a lecithin and (c) at least one first agent comprising or, alternatively, consisting of (c-i) autester or a fatty acid carbohydrate ester.
  • a preferred embodiment of the present invention relates to a berberine formulation in solid form comprising or, alternatively, consisting of: (a) berberine (as such or atomised), (b) a lecithin and (c) at least one first agent comprising or, alternatively, consisting of (c-v) a gum selected from the group comprising or, alternatively, consisting of : carrageenan, acacia gum and mixtures thereof.
  • a preferred embodiment of the present invention relates to a bergamot formulation in solid form comprising or, alternatively, consisting of: (a) bergamot, (b) a lecithin and (c) at least one first agent comprising or, alternatively, consisting of (c-v) a gum selected from the group comprising or, alternatively, consisting of : carrageenan, acacia gum and mixtures thereof.
  • the preferred formulations can comprise d) a starch, preferably of plant origin; even more preferably said starch of plant origin is gelatinised or pre-gelatinised; even more preferably said (d) starch of plant origin is selected from the group comprising or, alternatively, consisting of rice starch and/or corn starch; advantageously said (d) is rice starch, optionally pre-gelatinised.
  • said (a) berberine (as such or atomised), is comprised in a range from 10% to 90%, preferably from 30% to 80%, more preferably from 40% to 70%, for example about 51+1%;
  • said (b) lecithin preferably solid lecithin (E322), is comprised in a range from 0.05% to 20%, preferably from 0.1% to 10%, more preferably from 0.5% to 2%, for example about 1+0,5%;
  • said (c) first agent such as (c-i) or (c-v), preferably (c-i)ophenyl-(E473), is comprised in a range from 1% to 75% with respect to the weight of the preparation, preferably from 1% to 60%, more preferably from 5% to 40%, for example about 22+1%;
  • said (d) starch preferably pre-gelatinised rice starch, is comprised in a range from 1% to 88%, preferably from 1% to 50% or 60%, more preferably from 15% to 40%, or from 5% to 15% for example about 17% or 10%+1%.
  • said (a) bergamot is comprised in a range from 10% to 90%, preferably from 30% to 80%, more preferably from 40% to 70%, for example about 51+1%;
  • said (b) lecithin preferably solid lecithin (E322), is comprised in a range from 0.05% to 20%, preferably from 0.1% to 10%, more preferably from 0.5% to 2%, for example about 1+0,5%;
  • said (c) first agent such as (c-i) or (c-v), preferably (c-i)utester (E473)
  • said (d) starch preferably pre-gelatinised rice starch, is comprised in a range from 1% to 70%, preferably from 1% to 50%, more preferably from 20% to 40%, for example about or 32+1%.
  • said (a) berberine (as such or atomised), is comprised in a range from 10% to 90%, preferably from 30% to 80%, more preferably from 40% to 70%, for example about 51+1%;
  • said (b) lecithin, preferably solid lecithin (E322), is comprised in a range from 0.05% to 20%, preferably from 0.1% to 10%, more preferably from 0.5% to 2%, for example about 1+0,5%; said (c) at least one first agent comprising or, alternatively, consisting of (c-v) at least one gum selected from the group comprising or, alternatively, consisting of carrageenan, acacia gum and mixtures thereof, at an amount by weight comprised from 1% to 75%, preferably from 10% to 60%, more preferably from 15% to 40% with respect to the total weight of the formulation, with respect to the total weight of the formulation; and
  • said (d) starch preferably pre-gelatinised rice starch, is comprised in a range from 1% to 70%, preferably from 1% to 40%, more preferably from 5% to 20%, for example about or 10+1%.
  • said (a) bergamot is comprised in a range from 10% to 90%, preferably from 30% to 80%, more preferably from 40% to 70%, for example about 51+1%;
  • said (b) lecithin, preferably solid lecithin (E322), is comprised in a range from 0.05% to 20%, preferably from 0.1% to 10%, more preferably from 0.5% to 2%, for example about 1+0,5%; said (c) at least one first agent comprising or, alternatively, consisting of (c-v) at least one gum selected from the group comprising or, alternatively, consisting of carrageenan, acacia gum and mixtures thereof, at an amount by weight comprised from 1% to 75%, preferably from 10% to 60%, more preferably from 15% to 40% with respect to the total weight of the formulation, with respect to the total weight of the formulation; and
  • said (d) starch preferably pre-gelatinised rice starch, is comprised in a range from 1% to 70%, preferably from 10% to 60%, more preferably from 20% to 40%, for example about or 32+1%.
  • said first agent (c) comprises or alternatively consists of a mixture of (c-i) and (c-v)
  • the latter are preferably at a weight ratio comprised from 1:10 to 10:1, more preferably comprised from 1:5 to 5:1, even more preferably comprised from 1:3 to 3:1, for example 1:1.
  • both berberine and bergamot can be present.
  • said (a) is a mixture of bergamot and berberine
  • the latter are preferably at a weight ratio comprised from 1:10 to 10:1, preferably comprised from 1:5 to 5:1, even more preferably comprised from 1:3 to 3:1, for example 1:1.
  • the berberine and/or bergamot formulation further comprises, together with (a), (b) and (c) such as (c-i) or (c-v) a (d) starch of plant origin, preferably gelatinised or pre gelatinised; preferably, said (d) starch of plant origin is selected from rice starch and/or corn starch; preferably, said (d) starch of plant origin is rice starch (Oryza sativa) or native rice starch; more preferably, said (d) starch of plant origin is pre-gelatinised rice starch.
  • compositions preferably in solid form, comprising or, alternatively, consisting of: the berberine and/or bergamot formulation comprising or, alternatively, consisting of (a), (b), (c) such as (c-i) or (c-v) and, optionally, (d) according to any one of the embodiments described in the present invention and, optionally, at least one acceptable pharmaceutical or food grade additive and/or excipient.
  • the berberine and/or bergamot formulation comprising or, alternatively, consisting of (a), (b), (c) such as (c-i) or (c-v) and, optionally, (d) according to any one of the embodiments described in the present invention and, optionally, at least one acceptable pharmaceutical or food grade additive and/or excipient.
  • Said at least one acceptable pharmaceutical or food grade additive and/or excipient can be selected from all substances known to the man skilled in the pharmaceutical art or skilled in preparing food products, such as preservatives, emulsifiers and/or thickeners such as for example hydroxymethyl cellulose, sweeteners, dyes such as for example E171 dye, natural and artificial flavours, antioxidants, stabilisers, fillers, anticaking agents such as for example vegetable magnesium stearate, fatty acid magnesium salts and silicon dioxide, bulking agents such as for example microcrystalline cellulose and mixtures thereof.
  • preservatives such as for example hydroxymethyl cellulose
  • sweeteners dyes such as for example E171 dye, natural and artificial flavours, antioxidants, stabilisers
  • anticaking agents such as for example vegetable magnesium stearate, fatty acid magnesium salts and silicon dioxide
  • bulking agents such as for example microcrystalline cellulose and mixtures thereof.
  • the composition of the invention comprises a berberine and/or bergamot formulation of the invention comprising or, alternatively, consisting of (a), (b), (c-i) and, optionally, (d) according to any one of the described embodiments.
  • composition of the invention comprising a berberine and/or bergamot formulation comprising or, alternatively, consisting of (a), (b), (c) such as (c-i) or (c-v) and, optionally, (d) according to any one of the described embodiments, further comprises at least one or more further active components selected from the group comprising or, alternatively, consisting of: - (e) at least one vitamin selected from the group of vitamins comprising or, alternatively, consisting of: (e- i) a vitamin of group C, (e-ii) a vitamin of group E, (e-iii) a vitamin of group B, preferably vitamin B6 and/or B9 and/or B12, (e-iv) a vitamin of group D, preferably vitamin D3, and mixtures thereof; preferably (e-i) vitamin C (L-ascorbic acid and/or L-sodium ascorbate);
  • (f) at least one organic salt or inorganic salt preferably selected from the group comprising or, alternatively, consisting of: (f-i) magnesium glycinate, (f-ii) selenium methionine, (f-iii) zinc gluconate and mixtures thereof;
  • At least one antioxidant preferably selected from the group comprising or, alternatively, consisting of: (g-i) N-acetylcysteine (NAC), (g-ii) Coenzyme Q10 (CoQ10), (g-iii) Acetyl-L-carnitine (ALC) and mixtures thereof;
  • At least one bacterial strain belonging to the genus Lactobacillus or Bifidobatterium preferably of the species selected from the group comprising or, alternatively, consists of: Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus reuteri, Lactobacillus rhamnosus, Bifidobacterium lungum, Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium bifidum and mixtures thereof; and
  • red fermented rice ( Monascus purpureus ), preferably red fermented rice titrated in monacolin to a % by weight comprised in a range from 2% to 10%, preferably from 3% to 7%, more preferably to about 5%, with respect to the weight of red rice (in short, % w/w), wherein said monacolin is preferably monacolin K.
  • Red fermented rice is the product of the fermentation of the common rice (Oryza sativa) by the yeast Monascus purpureus (red yeast), according to the techniques known to the man skilled in the art.
  • the production process of red fermented rice in Japan is known as Koji and is a very ancient technique.
  • the common rice takes the red colouring typical of yeast and it is enriched with many active substances, including monacolin, including monacolin K.
  • the composition of the invention comprises a berberine and/or bergamot formulation comprising or, alternatively, consisting of (a), (b), (c) such as (c-i) or (c-v) and, optionally, (d) according to any one of the described embodiments, and it further comprises (I) red fermented rice (, Monascus Purpureus), preferably red fermented rice titrated in monacolin to a % by weight comprised in a range from 2% to 10%, preferably from 3% to 7%, more preferably to about 5% with respect to the weight of red rice, wherein said monacolin is preferably monacolin K.
  • red fermented rice preferably red fermented rice titrated in monacolin to a % by weight comprised in a range from 2% to 10%, preferably from 3% to 7%, more preferably to about 5% with respect to the weight of red rice, wherein said monacolin is preferably monacolin K.
  • the composition of the invention comprises a berberine and/or bergamot formulation comprising or, alternatively, consisting of (a), (b), (c-i) and, optionally, (d) according to any one of the described embodiments, and said composition further comprises (I) red fermented rice ( Monascus Purpureus), preferably red fermented rice titrated in monacolin to a % by weight comprised in a range from 2% to 10%, preferably from 3% to 7%, more preferably to about 5% with respect to the weight of red rice, wherein said monacolin is preferably monacolin K.
  • red fermented rice Monascus Purpureus
  • monacolin preferably monacolin K.
  • the composition of the invention comprises a berberine and/or bergamot formulation comprising or, alternatively, consisting of (a), (b), (c-v) and, optionally, (d) according to any one of the described embodiments, and said composition further comprises (I) red fermented rice ( Monascus Purpureus), preferably red fermented rice titrated in monacolin to a % by weight comprised in a range from 2% to 10%, preferably from 3% to 7%, more preferably to about 5% with respect to the weight of red rice, wherein said monacolin is preferably monacolin K.
  • red fermented rice Monascus Purpureus
  • monacolin preferably monacolin K.
  • said (I) red fermented rice ( Monascus purpureus) titrated in monacolin or monacolin K to 2%- 10% or 3%-7% or about 5% w/w, is present in the composition of the invention at a % by weight so that said monacolin or monacolin K is comprised in the composition in a range from 0.05% to 1.00% with respect to the total weight of the composition, preferably from 0.10% to 0.50%.
  • each single vitamin (e) and/or salt (f) is present in the composition of the invention at an amount equal to 100% RDA (recommended dietary allowance).
  • each single antioxidant substance (g) is present in the composition of the invention in an amount equal to 100 mg/day.
  • compositions of the invention are in solid form, for example in solid form as such or in mouth-soluble solid form (or mouth-dispersible form, or that dissolve in the oral cavity), preferably in solid form as such.
  • compositions of the invention can be in liquid form, for example in the form of solution, dispersion or suspension of a solid in a liquid, or in semi-solid form, for example in form of creams or gels or soft-gels.
  • compositions of the invention are formulated for oral administration (in short, per os).
  • compositions of the invention are in solid form for oral administration, such as for example powder, granules, flakes, tablets or capsules. If the compositions of the invention are in tablet form, said tablet may have a weight comprised in the range from 200 mg to 2000 mg, for example a hard tablet from 800 mg to 1000 mg.
  • Said tablets may be coated or filmed with one or more coating layers or films capable of going past the gastric barrier.
  • Said coating may comprise bee wax or a sugar-based solution.
  • compositions of the invention are in the form of a capsule
  • said capsule may be of hard gelatine or soft gelatine or soft-gel; preferably a gelatine capsule may have a weight comprised in the range of from 100 mg to 1500 mg, more preferably about 800 mg.
  • composition of the invention comprising said berberine and/or bergamot formulation according to any one of the embodiments described in the present invention, may be a pharmaceutical composition, a medical device composition, a dietary supplement, a food or novel food or nutraceutical composition.
  • the expression "medical device” is used in the meaning according to the Italian Legislative Decree n° 46 dated 24 February 1997 or according to the new Medical Device Regulation (EU) 2017/745 (MDR).
  • Forming an object of the present invention is the composition or berberine and/or bergamot formulation, according to any one of the described embodiments, for use as medicament.
  • composition or the berberine and/or bergamot formulation for use in a method for preventive and/or curative treatment of a disease, symptom and/or disorder related with a dyslipidaemia or impairment of the lipid metabolism, in subjects in need.
  • said diseases, symptoms and/or disorders related with a dyslipidaemia or impairment of the lipid metabolism are selected from:
  • LDL or LDL cholesterol low-density lipoprotein
  • HDL or HDL cholesterol high-density lipoprotein
  • abnormal levels is used to indicate higher or lower levels with respect to the ranges within which triglyceride or LDL or HDL levels fall in the blood or plasma of healthy subjects as determined by health care organisations (in short, normal or near optimal ranges). Said standard ranges may vary over time and from population to population.
  • LDL cholesterol should ideally not exceed 100 mg/dl, although levels below 160 mg/dl are considered normal.
  • HDL cholesterol should be equal to or above 50 mg/dl.
  • Total cholesterol is considered “moderately high” when the blood concentrations thereof are between 200 and 239 mg/dl and "high” when equal to or above 240 mg/dL.
  • LDL-cholesterol concentration is instead considered “almost optimal” for values between 100 and 129 mg/dl, “moderately high” for values between 130 and 159 mg/dl, “high” for values between 160 and 189 mg/dl, and “very high” for values exceeding 190 mg/dl.
  • HDL cholesterol is considered to be “low” when the blood concentrations thereof fall below 40 mg/dl and "high” when they are equal to or above 60 mg/dl.
  • the composition of the invention and the berberine and/or bergamot formulation of the invention are for use in a method for the preventive and/or curative treatment of (i) hypercholesterolemia, more preferably the composition of the invention is for use in a method for preventive and/or curative treatment of (ii) modulation or decrease in plasma LDL cholesterol levels and/or of (iii) modulation or increase in plasma HDL cholesterol levels and/or (iv) modulation or decrease in plasma triglyceride levels.
  • Atherosclerosis is characterised by the presence of inhomogeneous intima plaques (atheromas) which invade the lumen of medium and large arteries; the plaques contain lipids, inflammatory cells, smooth muscle cells and connective tissue. Risk factors comprise dyslipidaemia, diabetes, cigarette smoking, family medical history, sedentary life, obesity and hypertension. Symptoms appear when plaque growth or rupture obstructs or decreases blood flow; symptoms vary depending on the artery involved. Atherosclerosis is responsible for coronary and cerebrovascular diseases (for example, stroke).
  • Metabolic syndrome is characterised by a large waist circumference (due to excess abdominal fat), arterial hypertension, impaired fasting plasma glucose or insulin resistance and dyslipidaemia. The causes, complications, diagnosis and treatment are similar to those of obesity.
  • an amount of the composition of the invention comprising or, alternatively, consisting of the berberine and/or bergamot formulation according to the invention so as to provide the administration of an amount of berberine as such comprised in the range from 100 mg to 1,500 mg, preferably from 300 mg to 800 mg, more preferably from 400 mg to 600 mg, for example about 500 mg.
  • composition of the invention comprises the berberine and/or bergamot formulation and red fermented rice ( Monascus purpureus), preferably red fermented rice titrated in monacolin or monacolin K to 2%-10% or 3%-6% or about 5% w/w
  • red fermented rice preferably red fermented rice titrated in monacolin or monacolin K to 2%-10% or 3%-6% or about 5% w/w
  • red fermented rice comprised in the range from 10 mg to 100 mg, preferably from 40 mg to 80 mg, more preferably from 50 mg to 70 mg, for example about 60 mg.
  • the composition of the invention comprises the berberine and/or bergamot formulation and red fermented rice titrated in monacolin or monacolin K to about 5% w/w
  • the daily oral administration of an amount of the composition of the invention so as to provide the administration of an amount of berberine as such of about 500 mg and an amount of red fermented rice ( Monascus purpureus) titrated in monacolin or monacolin K to about 5% w/w, of about 60 mg.
  • the composition of the invention is about 1000 mg and it comprises about 500 mg of berberine as such and about 60 mg of red fermented rice titrated in monacolin or monacolin K to about 5% w/w (equivalent to about 3 mg of monacolin or monacolin K).
  • compositions of the invention or the berberine and/or bergamot formulation of the invention can be administered for a period of time comprised in the range from 7 days to 120 days.
  • Forming an object of the present invention is to the use of the composition of the invention or of the berberine formulation of the invention (sucrosomial ® berberine) in the therapeutic or non-therapeutic treatment of a disease, symptom and/or disorder related with a dyslipidaemia or impairment of the lipid metabolism, such as, for example, hypercholesterolemia, abnormal levels of blood triglycerides, abnormal levels of blood lipoproteins, atherosclerosis and related coronary and cerebrovascular diseases, preferably stroke and metabolic syndrome.
  • a disease, symptom and/or disorder related with a dyslipidaemia or impairment of the lipid metabolism such as, for example, hypercholesterolemia, abnormal levels of blood triglycerides, abnormal levels of blood lipoproteins, atherosclerosis and related coronary and cerebrovascular diseases, preferably stroke and metabolic syndrome.
  • composition of the invention or the berberine formulation of the invention in the therapeutic or non-therapeutic treatment of a disease, symptom and/or disorder related with an impairment of the glucose metabolism, such as, for example, diabetes, preferably type 2 diabetes mellitus, hyperglycaemia, insulin resistance, high glucose uptake level, deregulation of the blood glucose level and metabolic syndrome conditions.
  • Forming an object of the present invention is a method for the preventive and/or curative treatment of a disease, symptom and/or disorder related with a dyslipidaemia or impairment of the lipid metabolism, such as, for example, hypercholesterolemia, abnormal levels of blood triglycerides, abnormal levels of blood lipoproteins, atherosclerosis and related coronary and cerebrovascular diseases, preferably stroke, and metabolic syndrome, wherein said method provides for the administration of the composition of the invention or of the berberine formulation of the invention (sucrosomial ® berberine) to a subject in need.
  • a disease, symptom and/or disorder related with a dyslipidaemia or impairment of the lipid metabolism such as, for example, hypercholesterolemia, abnormal levels of blood triglycerides, abnormal levels of blood lipoproteins, atherosclerosis and related coronary and cerebrovascular diseases, preferably stroke, and metabolic syndrome
  • said method provides for the administration of the composition of the invention or of the berberine formulation of the invention
  • an object of the present invention is a method for the preventive and/or curative treatment of a disorder related with an impairment of the glucose metabolism, such as, for example, diabetes, preferably type 2 diabetes mellitus, hyperglycaemia condition, insulin resistance conditions, high glucose uptake condition, deregulation of blood glucose level and metabolic syndrome conditions, and of symptoms and/or disorders related with said conditions, wherein said method provides for the administration of the composition of the invention or the berberine formulation of the invention (sucrosomial ® berberine) to a subject in need.
  • a disorder related with an impairment of the glucose metabolism such as, for example, diabetes, preferably type 2 diabetes mellitus, hyperglycaemia condition, insulin resistance conditions, high glucose uptake condition, deregulation of blood glucose level and metabolic syndrome conditions, and of symptoms and/or disorders related with said conditions
  • said method provides for the administration of the composition of the invention or the berberine formulation of the invention (sucrosomial ® berberine) to a subject in need.
  • Forming an object of the present invention is a process for the preparation of the berberine formulation of the invention (sucrosomial ® berberine).
  • the term "sucrosomial ® berberine” indicates a berberine formulation that can be obtained by processing berberine (a) together with a lecithin (b), a first agent (c) such as a withster (c-i) or a cyclodextrin (c-ii) or a fatty acid (c-iii) or a chitosan derivative (c-iv) and, optionally, a starch (d), according to said first process or said second process, described above.
  • sucrosomial ® berberine comprising or, alternatively, consisting of:
  • (c-iii) at least one fatty acid having a number of carbon atoms comprised in the range from C6 to C18;
  • sucrosomial ® berberine comprises or, alternatively, consists of:
  • FRa 3 The berberine formulation according to embodiment 1 or 2, wherein said formulation further comprises (d) a gelatinised or pre-gelatinised starch of plant origin; preferably, wherein said (d) starch of plant origin is selected from rice starch and/or corn starch; preferably, wherein said (d) is pre-gelatinised rice starch.
  • FRa 4 The berberine formulation according to any one of embodiments 1- 3, wherein said (c) at least one first agent is selected from the group comprising or, alternatively, consisting of:
  • said (c-i) is ahester E473; preferably ahester E473 comprising at least 70% by weight, with respect to the total weight of the interrupted acid, of monoesters obtained through the esterification of sucrose with one or more fatty acids of plant origin, preferably stearic acid and/or palmitic acid;
  • said (c-iv) at least one chitosan derivative, wherein said (c-iv) is a carboxymethyl chitosan; and mixtures thereof.
  • a composition comprising or, alternatively, consisting of:
  • sucrosomial ® berberine the berberine formulation in solid form, called sucrosomial ® berberine, according to any one of the embodiments 1- 4, and, optionally,
  • FRa 7 The composition according to embodiment 5 or 6, wherein said composition is for use as medicament.
  • FRa 10 The composition for use according to embodiment 7, wherein said composition is for use in a method for the preventive and/or curative treatment of a disease, symptom and/or disorder related with an impairment of the glucose metabolism.
  • FRa 11 The composition for use according to embodiment 10, wherein said composition is for use in a method for the preventive and/or curative treatment of:
  • diabetes preferably type 2 diabetes mellitus
  • a berberine formulation in solid form for use in a method for preventive and/or curative treatment of a disease, symptom and/or disorder related with a dyslipidemia or an impairment of the lipid metabolism wherein said berberine formulation in solid form, called sucrosomial ® berberine, comprising or, alternatively, consisting of:
  • (c-iii) at least one fatty acid having a number of carbon atoms comprised in the range from C6 to C18;
  • FRb 2 The berberine formulation in solid form for use according to FRb 1, wherein said formulation is for use in a method for preventive and/or curative treatment of a hypercholesterolemia and of symptoms and/or disorders related therewith.
  • FRb 3 The berberine formulation in solid form for use according to FRb 1, wherein said formulation is for use in a method for preventive and/or curative treatment of decrease in the plasma LDL cholesterol levels.
  • FRb 4 The berberine formulation in solid form for use according to FRb 1, wherein said formulation is for use in a method for preventive and/or curative treatment increase in the plasma HDL cholesterol levels.
  • FRb 5 The berberine formulation in solid form according to FRb 1, wherein said formulation is for use in a method for preventive and/or curative treatment of decrease in the blood or plasma triglyceride levels.
  • FRb 6 The berberine formulation in solid form for use according to FRb 1, wherein said formulation is for use in a method for preventive and/or curative treatment of an atherosclerosis or a relative coronary or cerebrovascular disease, preferably stroke, and of symptoms and/or disorders related therewith.
  • FRb 7 The berberine formulation in solid form for use according to FRb 1, wherein said formulation is for use in a method for preventive and/or curative treatment of a metabolic syndrome and of symptoms and/or disorders related therewith.
  • FRb 8 The berberine formulation in solid form for use according to any one of FRbs 1- 7, wherein said (c) at least one first agent comprises or, alternatively, consists of (c-i) a withster or a fatty acid carbohydrate ester.
  • FRb 9 The berberine formulation in solid form for use according to any one of FRbs 1-8, wherein said formulation further comprises (d) a gelatinised or pre-gelatinised starch of plant origin; preferably, wherein said (d) starch of plant origin is selected from rice starch and/or corn starch; preferably, wherein said (d) is pre-gelatinised rice starch.
  • FRb 10 The berberine formulation in solid form for use according to any one of FRbs 1- 9, wherein said (c) at least one first agent is selected from among the group comprising or, alternatively, consisting of:
  • said (c-i) is ahester E473; preferably ahester E473 comprising at least 70% by weight, with respect to the total weight of the interrupted acid, of monoesters obtained through the esterification of sucrose with one or more fatty acids of plant origin, preferably stearic acid and/or palmitic acid;
  • said (c-iii) at least one fatty acid, wherein said (c-iii) is a fatty acid having a number of carbon atoms comprised in the range from C12 to C18;
  • said (c-iv) at least one chitosan derivative, wherein said (c-iv) is a carboxymethyl chitosan; and mixtures thereof.
  • FRcn are object of the present invention.
  • FRc 1 A formulation in solid form comprising or, alternatively, consisting of:
  • (c-v) at least one gum selected from the group comprising or, alternatively, consisting of: carrageenan, acacia gum, and a mixture of (c-i) and (c-v).
  • FRc 2 A formulation in solid form according to FRc 1 comprising or, alternatively, consisting of:
  • said at least one first agent selected from the group comprising or, alternatively, consisting of:
  • (c-v) at least one gum selected from the group comprising or, alternatively, consisting of: carrageenan, acacia gum and a mixture of (c-i) and (c-v).
  • FRc 3 The formulation in solid form according to claim FRc 1, comprising or, alternatively, consisting of:
  • said at least one first agent selected from the group comprising or, alternatively, consisting of:
  • (c-v) at least one gum selected from the group comprising or, alternatively, consisting of: carrageenan, acacia gum, and and a mixture of (c-i) and (c-v).
  • FRc 4 The formulation according to any one of the preceding FRcs, wherein said formulation further comprises (d) a starch; preferably, wherein said (d) starch is of plant origin; even more preferably said starch of plant origin is gelatinised or pre-gelatinised.
  • FRc 5 The formulation according to FRc 4, wherein said (d) starch of plant origin is selected from the group comprising or, alternatively, consisting of rice starch and/or corn starch; preferably, wherein said (d) is pre-gelatinised rice starch.
  • FRc 6 The formulation according to any one of the preceding FRcs, wherein said formulation comprises, or alternatively, consists of:
  • FRc 7 The formulation according to any one of the preceding FRcs, wherein said formulation comprises or, alternatively, consists of:
  • At least one first agent comprising or, alternatively, consisting of (c-v) at least one gum selected from the group comprising or, alternatively, consisting of carrageenan, acacia gum and mixtures thereof;
  • FRc 8 The formulation according to any one of the preceding FRcs, wherein said formulation comprises or, alternatively, consists of:
  • FRc 9 The formulation according to FRc 8, wherein said mixture (c-i) and (c-v) are at a weight ratio comprised from 1:10 to 10:1, preferably comprised from 1:5 to 5:1, even more preferably comprised from 1:3 to 3:1, for example 1:1.
  • FRc 10 A composition comprising or, alternatively, consisting of:
  • FRc 11 The composition according to FRc 10, wherein said composition further comprises red fermented rice; preferably fermented red rice titrated in monacolin to a weight % comprised from 2% to 10%, preferably from 3% to 7%, more preferably to about 5%, with respect to the weight of red rice.
  • FRc 12 A formulation according to any one of FRcs 1-9 or a composition according to claim 10 or 11, wherein said composition is for use as medicament.
  • FRc 13 The formulation or the composition for use according to claim 11, wherein said formulation or composition is for use in a method for the preventive and/or curative treatment of a disease related with dyslipidaemia and/or hypercholesterolaemia.
  • FRc 14 The formulation or the composition for use according to FRc 13, wherein said formulation or composition is for use in a method for the preventive and/or curative treatment of decrease or normalisation of the plasma levels of total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides.
  • FRc 15 The formulation or the composition for use according to FRc 13, wherein said formulation or composition is for use in a method for the preventive and/or curative treatment of decrease in the plasma LDL cholesterol levels.
  • FRc 16 The formulation or the composition for use according to FRc 13, wherein said formulation or composition is for use in a method for the preventive and/or curative treatment of decrease in the blood or plasma triglyceride levels.
  • FRc 17 The formulation or the composition for use according to FRc 13, wherein said formulation or composition is for use in a method for the preventive and/or curative treatment of a disease related with atherosclerosis or a coronary or cerebrovascular disease, preferably stroke.
  • FRc 18 The formulation or the composition for use according to FRc 13, wherein said formulation or composition is for use in a method for the preventive and/or curative treatment of a metabolic syndrome and symptoms and/or disorders related therewith.
  • FRc 19 A process for the preparation of an atomised berberine carried on a carrier, wherein said process comprises the following steps:
  • step (I) providing an aqueous-based solvent, preferably water, in a container under stirring and heating and adding to said container a berberine, preferably a granular berberine, and plant starch, preferably rice starch, to obtain a mixture of step (I);
  • a berberine preferably a granular berberine, and plant starch, preferably rice starch
  • step (II) subjecting said mixture of step (I) to a nebulisation or atomisation step to obtain an atomised or nebulised berberine, and, optionally,
  • the purpose of the present trial is to predict the cholesterol lowering properties of the berberine formulation according to the present invention (sucrosomial ® berberine) using in vitro experimental models in LDL cholesterol metabolism.
  • human hepatocarcinoma cell lines HepG2 and Huh7
  • HepG2 and Huh7 were used to test the berberine formulations according to the present invention (sucrosomial ® berberine) on their ability to modulate the expression of genes involved in cholesterol and lipid metabolisms, such as LDL receptor, PCSK9, FIMG-CoA reductase, fatty acid synthase (FAS) and effect on LDL cholesterol uptake.
  • the concentration of berberine was first measured after extraction with water of 100 mg berberine as such and sucrosomial ® berberine.
  • HPLC analysis showed that the amounts of berberine after extraction - with water at room temperature - of 100 mg berberine as such (powder) and 100 mg sucrosomial® berberine (powder) with 1 ml of water were similar to each other and were about 3.1 mg/ml each ( Figure 1 and Table 2).
  • berberine having an MW of 336.36 g/mol the molar concentration of these basic preparations is equal to 9.2 mM.
  • sucrosomial ® berberine was compared with berberine as such in HepG2 cells after 24 hours of incubation.
  • the range of concentrations tested was comprised in the range from 2.5 mM to 40 mM.
  • Cell viability was determined by means of SRB assay (sulforhodamine B assay)
  • HuH7 cells were incubated with berberine as such or sucrosomial ® berberine at 10 mM and 20 mM for 24 hours. Subsequently, fluorescent-labelled LDL-cholesterol (DiO-LDL) was added to the growth medium (10 mg / ml of DiO-LDL) for 3 hours and cell fluorescence was determined by means of flow cytometry analysis (percentage of positive fluorescent cells).
  • DiO-LDL fluorescent-labelled LDL-cholesterol
  • sucrosomial ® berberine significantly induced LDL cholesterol uptake with respect to untreated control cells (in short, Crt). It should be noted that sucrosomial ® berberine is more efficient than berberine as such to induce the absorption of LDL cholesterol, as observed at the low concentration tested, i.e. 10 mM.
  • sucrosomial ® berberine with respect to berberine as such on LDL cholesterol uptake suggests a potential positive effect on expression of LDL receptor (in short, LDLR).
  • LDL receptor in short, LDLR
  • berberine increases the stability of the mRNA of the LDL receptor (LDLR) and, thus, the expression of LDLR.
  • sucrosomial ® berberine on LDLR mRNA levels and LDLR cell protein levels in the Huh7 cell line was evaluated by means of real time quantitative PCR (simultaneous DNA amplification and quantification method) and western blot analysis, respectively.
  • LDLR mRNA was significantly increased after only 24 hours of incubation with 20 mM of sucrosomial ® berberine ( Figure 4A). This induction is significantly higher than the LDLR mRNA levels in Huh7 cells incubated with berberine as such at 20mM ( Figure 4A).
  • sucrosomial ® berberine more efficiently induces LDL cholesterol uptake (in short, LDL-C) and the expression of LDL receptor (LDLR) with respect to berberine as such.
  • sucrosomial ® berberine In vitro evaluation of sucrosomial ® berberine on proteins involved in glucose metabolism.
  • sucrosomial ® berberine induced the expression of GK and the phosphorylation state of AMPK. This effect is slightly more pronounced with sucrosomial ® berberine with respect to berberine as such.
  • Huh7 cells were incubated in DMEM (Dulbecco's Modified Eagle's Medium) containing 25mM of glucose with indicated concentrations of berberine as such and sucrosomial ® berberine for 24 hours. After this period , the total cellular proteins were extracted for analysis.
  • DMEM Dulbecco's Modified Eagle's Medium
  • GK catalyses the conversion of glucose to glucose-6-phosphate and it is considered the guardian of glucose metabolism in hepatocytes.
  • glucose-6-phosphate can be further transformed into glucose-1 -phosphate (G-1-P) and synthesised into glycogen for storage or used by the cell through the tricarboxylic acid cycle and the pentose phosphate pathway.
  • Huh7 cells were incubated in DMEM containing 25mM of glucose with indicated concentrations of berberine as such and sucrosomial ® berberine for 24 hours. After this period, the total glycogen content was determined by means of ELISA test.
  • Sucrosomial ® berberine was more effective with respect to berberine as such, evidenced by a significant improvement of sucrosomial ® berberine with respect to berberine as such on the in vitro determination of the uptake of LDL cholesterol (LDL-C), on the expression of LDL receptor (both mRNA and proteins), GK and the phosphorylation status of AMPK.
  • LDL-C LDL cholesterol
  • LDL receptor both mRNA and proteins
  • GK phosphorylation status of AMPK
  • MEM Eagle's minimum essential medium
  • FCS foetal calf serum
  • FCS foetal calf serum
  • DiO was bought from Sigma.
  • Berberine as such and sucrosomial ® berberine were prepared by dissolving 10 mg of each compound in 1 ml of water.
  • HepG2, Huh7 and Caco2 cells were cultured in MEM supplemented with 10% FCS, L-glutamine, sodium pyruvate and non-essential amino acids, penicillin / streptomycin at 37°C in a humidified atmosphere at 5% CO2 and 95% air.
  • SRB sulforhodamine B
  • Total LDL (d >1.019 ⁇ 1.063 g / mL) was isolated from human plasma by means of ultracentrifugation at 4°C.
  • LDL samples were transferred in dialysis tubes and dialysed in physiological solution (0.9% NaCI in deionised water) at 4 °C, changing the solution three times (4 hours, 48 hours).
  • Purified LDLs were sterilised using a 0.22 m filter and stored at 4°C. The protein content was evaluated by the BCA assay, using BSA as a standard.
  • LDLs were incubated with the DiO fluorescent dye (250 pg of DiO / mg of LDL protein) for 18 hours at 4°C.
  • LDL-DiO was purified on a Sephadex G25 (PD10) column with 0.01% PBS-EDTA (pH 7.4), to remove unbound DiO.
  • Cells were seeded in a 96-well plate (25 x 10 3 cells / well in a complete medium) and after 24 hours they were treated in 0.4% FCS medium. 24 hours after treatment, the cells were incubated with 100 pg/mL LDL-DiO (3,3'-dioctadecyloxacarbocyanine). After 3 hours incubation at 37°C, the cells were analysed by means of flow cytometry analysis.
  • LDL-DiO 3,3'-dioctadecyloxacarbocyanine
  • RNA Preparation e "Quantitative Real Time PCR-Total RNA” were extracted using the reagents for the preparation of cDNA synthesis (Bio-Rad), iScriptTM RT-qPCR Sample Preparation Buffer (BIO-RAD), according to the manufacturer's instructions. Reverse synthesis of transcription-polymerase first strand cDNA was performed using the Maxima first Strand cDNA synthesis kit (Thermo Scientific). qPCR was then performed using PowerUpTM SYBRTM Green Master Mix (Thermo Scientific) and primers specific to selected genes.
  • the analyses were performed with Mx3000P qPCR System (Agilent), under the following cycle conditions: 95°C, 2 min; 95°C, 15 seconds and 60°C, 1 minute for 40 cycles.
  • the data were expressed as Ct values and used for the relative quantification of objectives with AAthe Ct calculation.
  • AAThe Cts were corrected by multiplying the value of the ratio between the efficiency of the specific primer and the “house keeping 18S”.
  • the cells were washed twice with PBS and lysed with a 50 mM solution of Tris pH 7.5, 150 mM NaCI, 0.5% Nonidet-P40, containing a cocktail of protease and phosphatase inhibitors (SIGMA, Milan, Italy) for 30 minutes, on ice. Twenty pg of proteins and a molecular mass marker (Thermo Scientific) were separated on SDS-PAGE 4-12% (BIO-RAD) under denaturation and reduction conditions. The proteins were then transferred onto a nitrocellulose membrane using the Trans-Blot® TurboTM (BIO-RAD) transfer system.
  • SIGMA protease and phosphatase inhibitors
  • the membranes were washed with Tris-Tween 20 (TBS-T) buffered saline solution and non specific binding sites were blocked in TBS-T containing 5% fat-free dried milk for 60 minutes at room temperature.
  • TBS-T Tris-Tween 20
  • the blots were incubated overnight at 4°C with a diluted solution (5% fat-free powdered milk) of the following primary human antibodies: anti-GK (Biovision, rabbit polyclonal; dilution 1 : 1,000), anti LDLR (mouse monoclonal antibody, Millipore clone 2H7.1; dilution 1: 1,000), anti-AMPK and phospho- AMPK (cell signalling, polyclonal antibodies) and anti-a-tubulin (mouse monoclonal antibody, Sigma clone DM1 A; dilution 1: 2,000).
  • anti-GK Biovision, rabbit polyclonal; dilution 1 : 1,000
  • anti LDLR m
  • the membranes were washed with TBS-T and then exposed for 90 minutes at room temperature to a diluted solution (5% fat-free powdered milk) of secondary antibodies (goat anti rabbit peroxidase-conjugated and anti-mouse, Jackson Immunoresearch). Immunoreactive bands were detected by exposing the membranes to the Western ClarityTM ECL (Bio-Rad) chemiluminescent substrates for 5 minutes and images were acquired using a VersaDoc 4000 Imaging System (Bio-Rad). Densitometric readings were evaluated using the ImageLabTM software as described above.
  • BBR-A Atomised berberine
  • Ultra-berberine (atomised sucrosomial berberine): Understood as a formulation comprising berberine carried on starch, lecithin,ester
  • Ultra-bergamot Understood as a formulation comprising bergamot, lecithin, and starch
  • Atomised berberine (BBR-A) can be obtained through the atomisation/nebulisation process described in the present invention.
  • Huh7s were incubated for 24 hours with increasing concentrations of formulations 1-4. At the end of the incubation the total proteins were extracted and the expression of LDLR, HMG-CoA and PCSK9 was determined by means of western blot analysis. As expected, berberine significantly increases expression of LDLR and reduces levels of PCSK9 ( Figure 8). The effect of atomised berberine and ultra berberine on the epsression of LDLR and PCSK9 in Huh7 cells was evaluated. Cells were cultured with MEM/0.4% FCS in the presence or absence of increasing concentrations of atomised berberine (BBR-A) and ultra- berine (U BBR).
  • BBR-A atomised berberine
  • U BBR ultra- berine
  • Huh7 was treated with the U-BBR formulation for 24 hours and then incubated with fluorescence-labelled LDL (LDL-DiO) for 3 hours. After incubation, LDL-DiO uptake was evaluated by means of cytofluorometry analysis. As shown in Figure 10, simvastatin and berberine increased LDL-DiO uptake by 2.6 and 3.4 folds, respectively. Ultra-berberine (U-BBR) (atomised sucrosomial berberine) induced high LDL uptake by more than 5 folds. No differences between atomised berberine and ultra-berberine were observed (Figure 10).
  • U-BBR atomised sucrosomial berberine
  • Ultra-berberine (atomised sucrosomial berberine) on LDL-DiO by Huh7 cells was tested.
  • Cells were cultured with MEM / 0,4% FCS in the presence or absence of increasing concentrations of atomised berberine (BBR-A) and ultra-berberine (U-BBR). After 24 hours, LDL-DiO was added to the growth medium and uptake was determined by means of cytofluorometry analysis.
  • Formulations vs control ** p ⁇ 0.01; *** p ⁇ 0.001.
  • formulations according to the present invention are effective in the treatment of hypercholesterolaemia and of the diseases related therewith.
  • MEM Eagle minimal essential Medium
  • trypsin-EDTA penicillin, streptomycin, sodium pyruvate, non-essential amino acid solution, foetal calf serum (FCS), Petri dishes and capsules were bought from EuroClone.
  • DiO will be bought from Sigma.
  • the natural products were supplied by PharmaNutra S.p.A (Pisa, Italy). Atomised berberine and ultra-berberine were dissolved in DMSO. Bergamot will be dissolved in saline solution.
  • Huh7s were cultured in MEM supplemented with 10% FCS, L-glutamine, sodium pyruvate and non- essential amino acids, penicillin/streptomycin at 37°C in a humidified atmosphere with 5% C02 and 95% air.
  • SRB sulforhodamine B
  • Huh7 cells were seeded in a 96-well tray (25 x 103 cells / well in a complete medium) and they were treated with nutraceuticals in a 0.4% FCS medium after 24 hours. 24 hours after treatment, the cells were incubated with 10 g / mL di LDL-DiO (CABRU s.a.s.). After 3 hours of incubation at 37°C, the cells were detached using trypsin and fluorescence intensity was determined by means of cytofluorometry analysis.
  • CABRU s.a.s. di LDL-DiO
  • RT-qPCR Reverse transcription and quantitative PCR
  • RNA preparation and Quantitative real-time PCR Total RNA were extracted using the iScriptTM RT-qPCR sample preparation reagent (Bio-Rad) according to the manufacturer's instructions.
  • One-step qPCR was performed using TranScriba 1step PCR Mix SYBR (CABRU s.a.s) and primers specific to selected genes. Analyses were performed using the CFX96 Touch Real-Time PCR Detection System (Bio-Rad). The data was expressed as Ct values and used for the relative quantification of the targets using the MCt. calculation. The II MCt was corrected by multiplying the value of the ratio between the efficiency of the specific primer and the housekeeping 18S.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une formulation de berbérine sous forme solide, appelée « berbérine sucrosomial® », comprenant ou, en variante, constitué de berbérine, d'une lécithine et d'un premier agent choisi parmi un sucrester, une cyclodextrine, un acide gras et un dérivé de chitosane, de préférence un sucrester. En outre, la présente invention concerne des compositions comprenant ladite berbérine sucrosomial® et, de manière facultative, du riz rouge et son utilisation dans le traitement d'un état de dyslipidémie ou d'une déficience du métabolisme des lipides, en particulier l'hypercholestérolémie, et/ou la déficience du métabolisme du glucose.
PCT/IB2020/060383 2019-11-04 2020-11-04 Berbérine bertrypanosomial®, ses compositions et leur utilisation Ceased WO2021090214A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IT102019000020300A IT201900020300A1 (it) 2019-11-04 2019-11-04 Uso di berberina sucrosomiale® e sue composizioni nel trattamento di dislipidemie
IT102019000020316A IT201900020316A1 (it) 2019-11-04 2019-11-04 Uso di berberina sucrosomiale® e sue composizioni nel trattamento di alterazioni del metabolismo glucidico
IT102019000020316 2019-11-04
IT102019000020290A IT201900020290A1 (it) 2019-11-04 2019-11-04 Berberina sucrosomiale®, sue composizioni e loro uso
IT102019000020300 2019-11-04
IT102019000020290 2019-11-04

Publications (2)

Publication Number Publication Date
WO2021090214A2 true WO2021090214A2 (fr) 2021-05-14
WO2021090214A3 WO2021090214A3 (fr) 2021-06-10

Family

ID=73695080

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2020/060383 Ceased WO2021090214A2 (fr) 2019-11-04 2020-11-04 Berbérine bertrypanosomial®, ses compositions et leur utilisation

Country Status (1)

Country Link
WO (1) WO2021090214A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115212182A (zh) * 2022-07-01 2022-10-21 广州长生康生物科技有限公司 一种大豆磷脂软胶囊及其制备方法和应用
IT202200003224A1 (it) * 2022-03-01 2023-09-01 Neilos S R L “Composizione nutraceutica o farmaceutica comprendente un estratto di riso rosso fermentato”
IT202200007388A1 (it) * 2022-04-13 2023-10-13 Anvest Group S R L Composizione per il trattamento della ipercolesterolemia
IT202200025929A1 (it) * 2022-12-19 2024-06-19 Akhynex S R L Composizioni comprendenti frazioni di frutto di bergamotto
WO2026018148A1 (fr) * 2024-07-15 2026-01-22 Next Herbals Llc Formulation à base de plantes pour la prise en charge de troubles métaboliques et son procédé de préparation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993805A (en) * 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
RU2147226C1 (ru) * 1994-09-29 2000-04-10 Квадрант Хэлткэа (Ю Кей) Лимитед Высушенные распылением микрочастицы как терапевтические носители
CN1269478C (zh) * 2004-06-14 2006-08-16 湖北丽益医药科技有限公司 盐酸小檗碱微囊及其制备方法
CN1273133C (zh) * 2004-11-12 2006-09-06 北京昭衍博纳新药研究有限公司 掩味盐酸小檗碱颗粒及其制剂
ITTO20060239A1 (it) * 2006-03-30 2007-09-30 Rotthapharm S P A Formulazione per somministrazione orale con effetti salutistici sull'apparato cardiovascolare
ITMI20081403A1 (it) * 2008-07-29 2010-01-30 Velleja Res Srl Composizioni comprendenti berberina e/o suoi analoghi o estratti che la contengano, per la prevenzione e il trattamento delle alterazioni del quadro lipidico e glucidico
CN102525952A (zh) * 2011-11-29 2012-07-04 昆明邦宇制药有限公司 一种黄连素微丸的生产方法
CN102793673A (zh) * 2012-09-07 2012-11-28 中国药科大学 一种小檗碱磷脂复合物固体分散体及其制备方法
CN104940167B (zh) * 2015-06-05 2018-01-23 厦门大学 一种负载黄连素磷脂复合纳米微粒的制备方法
US20180235870A1 (en) * 2015-08-17 2018-08-23 Delivra Inc. Transdermal formulations for delivery of berberine compounds, and their use in the treatment of berberine-responsive diseases and conditions
CN106038488B (zh) * 2016-07-19 2019-08-23 重庆医科大学 一种明显提高难溶性药物生物利用度的水包油型纳米乳及其制备方法
CN106511260B (zh) * 2016-12-05 2019-11-26 黑龙江童医生儿童生物制药有限公司 一种盐酸小檗碱口服微丸干凝胶及其制备方法和应用
CN108685870A (zh) * 2017-04-06 2018-10-23 中国医学科学院药物研究所 小檗碱及其可形成盐的肠溶微丸、其制备及应用
EP3672575A1 (fr) * 2017-08-25 2020-07-01 Eleonor SPRL Composition comprenant au moins un alcaloïde de type protoberbérine et son procédé de production
AU2019213699B2 (en) * 2018-02-02 2024-06-27 Indena S.P.A. Compositions comprising berberine

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202200003224A1 (it) * 2022-03-01 2023-09-01 Neilos S R L “Composizione nutraceutica o farmaceutica comprendente un estratto di riso rosso fermentato”
WO2023166413A1 (fr) * 2022-03-01 2023-09-07 Neilos S.r.l. Composition nutraceutique ou pharmaceutique contenant un extrait de levure de riz rouge
IT202200007388A1 (it) * 2022-04-13 2023-10-13 Anvest Group S R L Composizione per il trattamento della ipercolesterolemia
EP4260865A1 (fr) * 2022-04-13 2023-10-18 Anvest Group S.r.l. Composition comprenant des extraits vegetaux pour le traitement de l'hypercholesterolemie
CN115212182A (zh) * 2022-07-01 2022-10-21 广州长生康生物科技有限公司 一种大豆磷脂软胶囊及其制备方法和应用
IT202200025929A1 (it) * 2022-12-19 2024-06-19 Akhynex S R L Composizioni comprendenti frazioni di frutto di bergamotto
WO2026018148A1 (fr) * 2024-07-15 2026-01-22 Next Herbals Llc Formulation à base de plantes pour la prise en charge de troubles métaboliques et son procédé de préparation

Also Published As

Publication number Publication date
WO2021090214A3 (fr) 2021-06-10

Similar Documents

Publication Publication Date Title
US9345732B2 (en) Agents derived from Holoptelea integrifolia and their compositions for the control of metabolic syndrome and associated diseases
Alamgir Vitamins, nutraceuticals, food additives, enzymes, anesthetic aids, and cosmetics
CN102215853B (zh) 来自佛手柑果的植物复合物、制造方法及作为膳食补充剂和在制药领域中的应用
Tak et al. Jamun seed: A review on bioactive constituents, nutritional value and health benefits
US9895400B2 (en) Composition and use of Lactobacillus reuteri GMNL-263 in decreasing blood lipid levels
FR3095761A1 (fr) Composition nutraceutique pour induire une perte de poids et réduire la graisse abdominale
JP2021512062A (ja) ベルベリンを含む組成物
EP1967197A1 (fr) Utilisation de préparations, purifications et d'extraits d'aloe
JP5186253B2 (ja) 抗ウイルス活性強化組成物
FR3080989A1 (fr) Composition liquide comprenant un extrait de feuilles de cassis et du jus de pomme concentre
JP2013245213A (ja) ビワ葉培養エキス−シクロデキストリン包接物
WO2005110400A1 (fr) Inhibiteur de la lipase, inhibiteur de l’estérase du cholestérol, inhibiteur de l’absorption de graisses neutres, inhibiteur de l’absorption du cholestérol et inhibiteur de l’absorption de l’ester du cholestérol
WO2013108822A1 (fr) Extrait d'olive contenant du dé(rhamnosyl)-actéoside
JP2023505246A (ja) 無機物および／またはビタミンならびに多糖を含む製剤、その組成物ならびに前記無機物および／またはビタミンの補充におけるその使用
TW201943413A (zh) 含薑黃酮醇a及／或薑黃酮醇b之組合物
EP2397136B1 (fr) Composition anti-inflammatoire
TWI359667B (en) Formulation for oral administration having a healt
US20100008887A1 (en) Anti-obesity composition containing acacia bark derivative
US20190030111A1 (en) Detoxifying composition for oral administration and method for preparing same
JP2010077065A (ja) サラシア属植物を含有する経口用組成物
GB2535177A (en) Composition and use of lactobacillus reuteri GMNL-263 in decreasing blood lipid levels
NL2038963B1 (en) A composition that can quickly sober up and relieve moderate to mild fatty liver, as well as its use
US20250275982A1 (en) Solid form formulation comprising chromium or copper or a vitamin, compositions and uses thereof
JP4310567B2 (ja) 血中脂質改善剤
JP7405823B2 (ja) アメリカンクランベリー抽出物およびリン脂質を含む組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20817482

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20817482

Country of ref document: EP

Kind code of ref document: A2